Aarey Drugs

Why is Aarey Drugs & Pharmaceuticals Ltd falling/rising?

As of 11-Jul, Aarey Drugs & Pharmaceuticals Ltd's stock price is declining at Rs 85.46, down 2.0%, with a total drop of 4.49% over the last three days. This short-term trend is marked by high volatility and a significant decrease in investor participation.

As of 11-Jul, Aarey Drugs & Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at Rs 85.46, which reflects a change of -1.74 (-2.0%). This drop can be attributed to several factors. The stock has underperformed its sector by -2.27% today and has been on a consecutive fall for the last three days, accumulating a total decline of -4.49% during this period. <BR><BR>Additionally, the stock opened with a loss of -2% today and reached an intraday low of Rs 85.46, indicating a lack of upward momentum. The trading activity has shown high volatility, with an intraday volatility of 1665.7%, suggesting significant fluctuations in price. Furthermore, investor participation appears to be declining, as evidenced by a drastic fall in delivery volume by -99.96% compared to the 5-day average. <BR><BR>While the stock has shown positive returns over longer periods, such as +5.51% over the past month and +26.27% year-to-date, the recent performance indicates a short-term downward trend influenced by the factors mentioned.

Which are the latest news on Aarey Drugs?

What does Aarey Drugs do?

Aarey Drugs & Pharmaceuticals Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, with net sales of ₹189 Cr and a net profit of ₹2 Cr as of March 2026. It was incorporated in 1990 and converted to a public limited company in 1993.

Overview: <BR>Aarey Drugs & Pharmaceuticals Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History: <BR>The company was originally incorporated in 1990 as Niharika Textiles & Chemicals Private Limited. It underwent a status change in March 1993 when it was taken over by the Aarey Group and converted into a public limited company. The latest reported quarterly results show net sales and net profit for March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 189 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 2 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 228 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 51.00 <BR>Industry P/E: 21 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.32 <BR>Return on Equity: 3.00% <BR>Price to Book: 1.54<BR><BR>Contact Details: <BR>Address: E-34 MIDC Tarapur, Boisar Thane Maharashtra : 401506 <BR>Tel: 91-22-23455543 <BR>Website: http://www.aareydrugs.com

How big is Aarey Drugs?

As of 10th June, Aarey Drugs & Pharmaceuticals Ltd has a market capitalization of 228.00 Cr, with recent Net Sales of 472.27 Cr and a Net Profit of 4.52 Cr. The company reported Shareholder's Funds of 138.48 Cr and Total Assets of 290.59 Cr for the latest annual period ending in March 2025.

As of 10th June, Aarey Drugs & Pharmaceuticals Ltd has a market capitalization of 228.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Aarey Drugs reported Net Sales of 472.27 Cr and a Net Profit of 4.52 Cr.<BR><BR>For the latest annual period ending in March 2025, the company had Shareholder's Funds of 138.48 Cr and Total Assets amounting to 290.59 Cr.

Who are in the management team of Aarey Drugs?

The management team of Aarey Drugs includes Mihir R Ghatalia (Chairman & Managing Director), Nimit R Ghatalia (Executive Director), and several independent directors: Chetan K Mehta, Lalit Tulsiani, and Anil Mandal, along with Preeti Paresh Rathi (Company Secretary) and Bina Ghatalia (Additional Director).

The management team of Aarey Drugs includes the following individuals:<BR><BR>1. Mihir R Ghatalia - Chairman & Managing Director<BR>2. Chetan K Mehta - Independent Director<BR>3. Preeti Paresh Rathi - Company Secretary & Compliance Officer<BR>4. Lalit Tulsiani - Independent Director<BR>5. Nimit R Ghatalia - Executive Director<BR>6. Anil Mandal - Independent Director<BR>7. Bina Ghatalia - Additional Director<BR><BR>If you need more specific information about any of the members or their roles, feel free to ask!

Who are the peers of the Aarey Drugs?

Aarey Drugs' peers include Lyka Labs, Everest Organics, Gennex Lab, BDH Industries, Kerala Ayurveda, Nectar Lifesci, Syschem (India), Brooks Lab, and Sat Kartar. Aarey Drugs has below average management risk and a 1-year return of 45.51%, lower than BDH Industries' 49.43% but higher than Kerala Ayurveda's -64.41%.

Peers: The peers of Aarey Drugs are Lyka Labs, Everest Organics, Gennex Lab., BDH Industries, Kerala Ayurveda, Nectar Lifesci., Syschem (India), Brooks Lab., and Sat Kartar.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sat Kartar, while Good management risk is found at BDH Industries and Gennex Lab. Average management risk is present at Lyka Labs, Everest Organics, and Nectar Lifesci., while Below Average management risk is noted at Aarey Drugs, Kerala Ayurveda, Syschem (India), and Brooks Lab. Growth is Excellent at Sat Kartar, Good at Gennex Lab. and Syschem (India), Below Average at Lyka Labs, Everest Organics, Kerala Ayurveda, Aarey Drugs, Nectar Lifesci., and Brooks Lab., and the rest have not been specified. Capital Structure is Excellent at Gennex Lab. and BDH Industries, Good at Syschem (India), Below Average at Lyka Labs, Everest Organics, Kerala Ayurveda, Aarey Drugs, Nectar Lifesci., Brooks Lab., and the rest.<BR><BR>Return Snapshot: BDH Industries has the highest 1-year return at 49.43%, while Kerala Ayurveda has the lowest at -64.41%. Aarey Drugs has a 1-year return of 45.51%, which is significantly higher than Kerala Ayurveda but lower than BDH Industries. Additionally, the six-month return is negative for Kerala Ayurveda, Nectar Lifesci., Brooks Lab., and Syschem (India).

Should I buy, sell or hold Aarey Drugs & Pharmaceuticals Ltd?

Are Aarey Drugs & Pharmaceuticals Ltd latest results good or bad?

Aarey Drugs & Pharmaceuticals Ltd's latest results show strong revenue growth, with Q4 FY26 net sales up 96.48% quarter-on-quarter, but profitability remains a concern, with low margins and modest net profit, indicating operational challenges despite impressive sales figures.

Aarey Drugs & Pharmaceuticals Ltd's latest results present a mixed picture. On one hand, the company reported impressive revenue growth, with net sales reaching ₹189.47 crores in Q4 FY26, marking a 96.48% increase quarter-on-quarter and a 75.27% increase year-on-year. This is the highest quarterly revenue in the company's recent history, indicating strong sales momentum.<BR><BR>However, the profitability metrics raise concerns. The net profit for the same quarter was ₹1.56 crores, which, despite being a significant 173.68% increase from the previous quarter and a 231.91% increase year-on-year, remains modest relative to the revenue base. The operating profit margin is quite low at 2.29%, and the profit after tax (PAT) margin is a mere 0.82%, which is among the weakest in the pharmaceutical sector.<BR><BR>Additionally, the company faces structural challenges, as it struggles to convert revenue growth into sustainable profits. The return on equity is low at 4.20%, and the return on capital employed is even lower at 2.55%. These figures suggest that while the company is generating revenue, it is not effectively managing costs or leveraging its growth to enhance profitability.<BR><BR>In summary, while Aarey Drugs has shown strong revenue growth, the underlying profitability issues and low margins indicate that the results are not entirely positive. The company appears to be in a challenging position, balancing impressive sales figures with significant operational weaknesses.

When is the next results date for Aarey Drugs & Pharmaceuticals Ltd?

The next results date for Aarey Drugs & Pharmaceuticals Ltd is 29 May 2026.

The next results date for Aarey Drugs & Pharmaceuticals Ltd is scheduled for 29 May 2026.

How has been the historical performance of Aarey Drugs?

Aarey Drugs has experienced fluctuating financial performance, with net sales increasing to 473.94 Cr in March 2025 from 395.62 Cr in March 2024, but down from 492.68 Cr in March 2022. Profitability metrics, including operating profit and earnings per share, have generally declined, indicating challenges in maintaining consistent profitability.

Answer:<BR>The historical performance of Aarey Drugs shows a fluctuating trend in net sales and profitability over the years, with net sales reaching 473.94 Cr in March 2025, up from 395.62 Cr in March 2024, but down from 492.68 Cr in March 2022. The total operating income followed a similar pattern, peaking at 492.68 Cr in March 2022 before declining to 473.94 Cr in March 2025. The operating profit (PBDIT) has also seen a decline, from 14.02 Cr in March 2022 to 12.70 Cr in March 2025. Profit before tax increased slightly to 6.10 Cr in March 2025 from 5.34 Cr in March 2024, while profit after tax decreased to 4.02 Cr in March 2025 from 4.68 Cr in March 2024. The company's earnings per share (EPS) dropped to 1.43 in March 2025 from 1.67 in March 2024, reflecting the overall decline in profitability.<BR><BR>Breakdown:<BR>Aarey Drugs' financial performance has shown variability in key metrics over the years. Net sales increased from 395.62 Cr in March 2024 to 473.94 Cr in March 2025, although this is a decrease from the 492.68 Cr recorded in March 2022. Total operating income mirrored this trend, with a peak in March 2022 before falling to 473.94 Cr in March 2025. Operating profit (PBDIT) has declined from 14.02 Cr in March 2022 to 12.70 Cr in March 2025, indicating a downward trend in profitability. Profit before tax saw a slight increase to 6.10 Cr in March 2025, while profit after tax decreased to 4.02 Cr in the same period. The earnings per share (EPS) also fell to 1.43 in March 2025 from 1.67 in March 2024, reflecting the challenges faced by the company in maintaining profitability amidst fluctuating sales and operating income.

Is Aarey Drugs overvalued or undervalued?

As of November 17, 2025, Aarey Drugs is considered overvalued with a high PE ratio of 75.88, weak profitability indicated by a 2.47% ROE, and negative operational metrics, despite recent strong stock performance.

As of 17 November 2025, Aarey Drugs has moved from a fair to a risky valuation grade. The company appears to be overvalued, primarily indicated by its high PE ratio of 75.88 and an EV to EBITDA ratio of 134.14, which are significantly above industry norms. Additionally, the return on equity (ROE) stands at a mere 2.47%, reflecting weak profitability, while the EV to EBIT ratio is notably negative at -315.22, suggesting severe operational challenges.<BR><BR>In comparison to its peers, Aarey Drugs' valuation metrics are concerning. For instance, Elitecon International has a PE ratio of 294.38, indicating a very expensive valuation, while PTC India, which is considered very attractive, has a PE of just 7.56. Aarey Drugs' high valuation ratios, combined with its negative ROCE of -0.07%, further underscore its overvaluation status. Despite recent strong stock performance against the Sensex, with a year-to-date return of 68.93% compared to the Sensex's 8.72%, the underlying financial metrics suggest that the stock may not sustain its current price levels.

Who are the top shareholders of the Aarey Drugs?

The top shareholders of Aarey Drugs include promoter Bina Rajesh Ghatalia with 14.12%, and the highest public shareholder, India Opportunities Growth Fund Ltd - Pinewood, with 2.34%. Individual investors hold 45.79%, and there is one foreign institutional investor with 2.34%, with no pledged promoter holdings or mutual fund investments.

The top shareholders of Aarey Drugs include Bina Rajesh Ghatalia, who is the promoter with the highest holding at 14.12%. Additionally, the highest public shareholder is India Opportunities Growth Fund Ltd - Pinewood, holding 2.34%. The company also has individual investors holding a significant portion at 45.79%. Furthermore, there is one foreign institutional investor (FII) that holds 2.34% of the shares. Notably, there are no pledged promoter holdings and no mutual funds currently invested in the company.

What is the technical trend for Aarey Drugs?

As of June 5, 2025, Aarey Drugs shows a neutral technical stance with mixed signals: weekly indicators are bullish while daily trends are mildly bearish, suggesting caution despite potential upward movement indicated by Bollinger Bands.

As of 5 June 2025, the technical trend for Aarey Drugs has changed from mildly bearish to sideways. The weekly MACD is bullish, while the monthly MACD is mildly bearish, indicating mixed signals across time frames. The Bollinger Bands are bullish on both weekly and monthly charts, suggesting potential upward movement. However, daily moving averages are mildly bearish, which adds caution. The KST shows a bullish stance weekly but is mildly bearish monthly, and Dow Theory indicates a mildly bearish weekly trend with a mildly bullish monthly outlook. Overall, the current technical stance is neutral, with strength in the weekly indicators but caution from daily trends.

What is the bonus history of the Aarey Drugs?

Aarey Drugs & Pharmaceuticals Ltd issued a 1:5 bonus on June 25, 2012, granting shareholders one additional share for every five shares held, with a record date of June 26, 2012. This is the company's most recent bonus action.

Aarey Drugs & Pharmaceuticals Ltd has a bonus history that includes a notable issue on June 25, 2012. The company announced a 1:5 bonus issue, meaning that for every five shares held, shareholders received one additional share. The record date for this bonus was June 26, 2012. This was the most recent bonus action recorded for the company. If you have any more questions about Aarey Drugs or need further details, feel free to ask!

Has Aarey Drugs declared dividend?

Aarey Drugs & Pharmaceuticals Ltd has declared a 1% dividend, amounting to ₹0.10 per share, with an ex-date of December 13, 2018. Despite the dividend declaration, the dividend yield is 0%, and total returns over various periods show significant price appreciation, especially over five years.

Aarey Drugs & Pharmaceuticals Ltd has declared a 1% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 1%<BR>- Amount per share: 0.10<BR>- Ex-date: 13 Dec 18<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6 months period, the price return was -12.92%, the dividend return was 0%, resulting in a total return of -12.92%.<BR><BR>For the 1 year period, the price return was 21.16%, the dividend return was 0%, leading to a total return of 21.16%.<BR><BR>Over the 2 years period, the price return was 66.72%, the dividend return was 0%, culminating in a total return of 66.72%.<BR><BR>In the 3 years period, the price return was 50.85%, the dividend return was 0%, which resulted in a total return of 50.85%.<BR><BR>For the 4 years period, the price return was 55.93%, the dividend return was 0%, yielding a total return of 55.93%.<BR><BR>In the 5 years period, the price return was 155.4%, the dividend return was 0%, resulting in a total return of 155.4%.<BR><BR>Overall, Aarey Drugs has declared a dividend, but the dividend yield remains at 0%. The total returns over various periods show a mix of performance, with significant price returns in the longer term, particularly over 5 years.